Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 baricitinib in systemic lupus erythematosus
NL-OMON49315Phase 3Completed
- Sponsor
- PPD
- Start
- Nov 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in systemic lupus erythematosus (SLE) (3 arms), sponsored by PPD. Primary endpoint: SRI-4 response at Week 52. Started Nov 2019; status: completed.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON49315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49315.